3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Thrombocytopenia
4
Leukemia, Myeloid, Acute
4
Leukemia
3
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Jacobs syndrome
1
Congenital Abnormalities
1
Bone Neoplasms
1
Interventions
ruxolitinib
1
eltrombopag
1
Doxorubicin
1
Docetaxel
1
Cytarabine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pathologic Complete Response
×
eltrombopag
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts